Keytruda (pembrolizumab)

pCPA File Number: 23077
Negotiation Status:
Active Negotiation
Indication(s):
In combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0353-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable